

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test t⦠read more
Healthcare
Diagnostics & Research
7 years
USD
Exclusive to Premium users
$30.39
Price+8.54%
$2.39
$928.399m
Small
-
Premium
Premium
+2.5%
EBITDA Margin-2.0%
Net Profit Margin+6.3%
Free Cash Flow Margin+2.5%
EBITDA Margin-2.0%
Net Profit Margin+6.3%
Free Cash Flow Margin$357.278m
+3.8%
1y CAGR+19.5%
3y CAGR+29.7%
5y CAGR-$19.415m
+19.6%
1y CAGR-27.0%
3y CAGR-16.7%
5y CAGR-$0.66
+20.5%
1y CAGR-28.1%
3y CAGR-16.8%
5y CAGR$470.030m
$561.177m
Assets$91.147m
Liabilities$36.650m
Debt6.5%
-11.3x
Debt to EBITDA-$489k
-101.7%
1y CAGR+55.2%
3y CAGR+56.2%
5y CAGR